Penn’s innovation in process science combines with CBM manufacturing capability for large-scale gene therapy manufacturing capacity, testing and analytics.
Aims to generate and validate human-derived monoclonal antibodies against Ono's newly selected drug targets in the field of neurodegenerative diseases.